Immune Response to SARS-CoV-2 Vaccine and Following Breakthrough Omicron Infection in an Autoimmune Patient with Hashimoto's Thyroiditis, Pernicious Anemia, and Chronic Atrophic Autoimmune Gastritis: A Case Report.

COVID-19 Hashimoto’s Omicron SARS-CoV-2 autoimmune breakthrough mRNA neutralization vaccine

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
15 Mar 2022
Historique:
received: 14 02 2022
revised: 05 03 2022
accepted: 14 03 2022
entrez: 26 3 2022
pubmed: 27 3 2022
medline: 27 3 2022
Statut: epublish

Résumé

In healthy adults, hybrid immunity induced by prior SARS-CoV-2 infection followed by two doses of mRNA vaccination provide protection against symptomatic SARS-CoV-2 infection. However, the role of hybrid immunity in autoimmune patients against Omicron is not well documented. Here, we report a young autoimmune patient with prior infection and two doses of mRNA-1273 vaccination who was exposed to Omicron and developed a symptomatic disease. Prior to Omicron infection, the patient had strong neutralizing antibody titers against the vaccine strain, but no neutralization of Omicron. Post Omicron infection, high neutralizing titers against Omicron were observed. Furthermore, enhanced neutralizing antibody titers against other variants of concern-Alpha, Beta, Gamma, and Delta-were observed, suggesting an expansion of cross-reactive memory B-cell response by the SARS-CoV-2 Omicron infection. Autoimmune patients may require careful monitoring of immune function over time to optimize booster vaccine administration.

Identifiants

pubmed: 35335082
pii: vaccines10030450
doi: 10.3390/vaccines10030450
pmc: PMC8949984
pii:
doi:

Types de publication

Case Reports

Langues

eng

Subventions

Organisme : United States Food and Drug Administration
ID : Medical Countermeasures Initiative (MCMi) grant #OCET 2021-1565

Références

J Chem Inf Model. 2022 Jan 24;62(2):412-422
pubmed: 34989238
Sci Transl Med. 2020 Jul 1;12(550):
pubmed: 32513867
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2021 Dec;600(7888):197-199
pubmed: 34857948
Sci Immunol. 2022 Feb 3;:eabn8590
pubmed: 35113654
Front Immunol. 2022 Jan 27;13:825256
pubmed: 35154144
PLoS One. 2021 Mar 10;16(3):e0248348
pubmed: 33690649
Science. 2021 Mar 25;:
pubmed: 33766944
J Infect Dis. 2022 Jan 03;:
pubmed: 34979030
iScience. 2021 Sep 24;24(9):103006
pubmed: 34430803
Cell. 2022 Mar 3;185(5):872-880.e3
pubmed: 35123650
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
Lancet. 2021 Dec 11;398(10317):2126-2128
pubmed: 34871545

Auteurs

Emily Cluff (E)

Center for Biologics Evaluation and Research (CBER), Division of Viral Products, Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.

Lorenza Bellusci (L)

Center for Biologics Evaluation and Research (CBER), Division of Viral Products, Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.

Hana Golding (H)

Center for Biologics Evaluation and Research (CBER), Division of Viral Products, Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.

Surender Khurana (S)

Center for Biologics Evaluation and Research (CBER), Division of Viral Products, Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.

Classifications MeSH